Nested case (neuropathic symptoms) vs control (symptom-free) sample | ||||
---|---|---|---|---|
Variable | Total cohort remaining symptom-free N = 88 | Neuropathic symptom group N = 30 | Control group N = 30 | Total N = 60 |
Female sex, N (%) | 62 (70) | 22 (73) | 22 (73) | 44 (73) |
Age *, years | 31 (27 – 38) | 32 (26 - 35) | 34 (26 - 41) | 33 (26 - 37) |
Weight *, kg | 63 (56- 72) | 58.0 (52.5 - 68.5) | 59.5 (54.0 - 64.0) | 58.5 (53.0 - 68.0) |
Height *, m | 1.61 (1.56 - 1.69) | 1.58 (1.55 - 1.64) | 1.62 (1.57 - 1.65) | 1.61 (1.55 - 1.64) |
Body Mass Index *, kg/m2 | 23.3 (20.3 - 28.0) | 22.7 (20.1 - 28.0) | 22.6 (19.8 - 25.3) | 22.6 (19.8 - 28.0) |
dNRTI †, N (%) | 68 (77) | 24 (40) | 22 (37) | 46 (77) |
D4T/3TC/NNRTI | 68 (77) | 24 (40) | 22 (37) | 46 (77) |
AZT/3TC/NNRTI | 5 (6) | 2 (7) | 3 (10) | 5 (8) |
TDF/3TC/NNRTI | 15 (17) | 4 (13) | 5 (17) | 9 (15) |
Previous TB, N (%) | 25 (28) | 7 (23) | 7 (23) | 14 (23) |
< 1 year ago | 13 (15) | 3 (10) | 3 (10) | 6 (10) |
1 year ago | 1 (1) | 0 (0) | 0 (0) | 0 (0) |
2 years ago | 2 (2) | 0 (0) | 1 (3) | 1 (2) |
> 2 years ago | 9 (10) | 4 (13) | 3 (10) | 7 (12) |
Years since HIV diagnosis * | 1 (1-3.4) | 1 (1-3.5) | 2 (1-4) | 1 (1-3.8) |
WHO stage, N (%) | ||||
Stage 1 | 30 (34) | 6 (20) | 12 (40) | 18 (30) |
Stage 2 | 25 (28) | 18 (60) | 10 (33) | 28 (47) |
Stage 3 | 30 (34) | 5 (17) | 7 (23) | 12 (20) |
Stage 4 | 3 (3) | 1 (3) | 1 (3) | 2 (3) |
White cell count *, ×109/L | 5.1 (4.0 - 6.6) | 5.7 (3.9 - 6.4) | 5.7 (4.4 - 7.9) | 5.7 (4.3 - 7.1) |
CD4 T-cell count *, cells/mm3 | 163 (125 - 193) | 145 (109 - 181) | 138 (110 - 194) | 141 (110 - 189) |
CD4 T-cell count, N (%) | ||||
< 100 cells/mm 3 | 15 (17) | 5 (17) | 6 (20) | 11 (18) |
100 - 200 cells/mm 3 | 56 (64) | 19 (63) | 20 (67) | 39 (65) |
> 200 cells/mm 3 | 17 (19) | 6 (20) | 4 (13) | 10 (17) |
hs-CRP *, mg/L | 2.6 (0.9 - 6.5) | 2.6 (0.9 - 5.4) | 2.9 (0.9 - 6.7) | 2.7 (0.9 - 6.7) |